SIRPA and cancer: The CD47-SIRPα innate immune checkpoint is currently extensively studied in the context of cancer immunotherapy (2, 57), with a number of different agents in preclinical and/or clinical development, and ~35 ongoing clinical trials, carving out a path for potential therapeutic targeting of the CD47-SIRPα axis also in other diseases, including cardiovascular disease.